albendazole sulfoxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anthelminthics, tiabendazole derivatives	104	54029-12-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ricobendazole albendazole sulfoxide albendazole oxide rycobendazole	Albendazole oxide (also known as albendazole sulphoxide and ricobendazole) is a benzimidazole with a broad-spectrum anthelmintic used in veterinary medicine. It is also a metabolite of two other veterinary drugs: netobimin and albendazole. The mechanism of action of ricobendazole (albendazole sulfoxide), ensuring its anthelmintic activity, is associated with selective inhibition of beta-tubulin polymerization. It binds to the colchicine site of tubulin, inhibiting microtubule polymerization. It also exhibits anticancer activity, potentiating the effects of taxanes and inhibiting cell proliferation in breast cancer cells, non-small cell lung cancer (NSCLC) cells, and melanoma cells. Also, albendazole oxide has been shown to induce apoptosis in human cancer cell line HT-29, possibly by arresting the cell cycle at the G2/M phase. Molecular weight: 281.33 Formula: C12H15N3O3S CLOGP: 1.70 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 84.08 ALOGS: -2.50 ROTB: 5

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ricobendazole
albendazole sulfoxide
albendazole oxide
rycobendazole

Albendazole oxide (also known as albendazole sulphoxide and ricobendazole) is a benzimidazole with a broad-spectrum anthelmintic used in veterinary medicine. It is also a metabolite of two other veterinary drugs: netobimin and albendazole. The mechanism of action of ricobendazole (albendazole sulfoxide), ensuring its anthelmintic activity, is associated with selective inhibition of beta-tubulin polymerization. It binds to the colchicine site of tubulin, inhibiting microtubule polymerization. It also exhibits anticancer activity, potentiating the effects of taxanes and inhibiting cell proliferation in breast cancer cells, non-small cell lung cancer (NSCLC) cells, and melanoma cells. Also, albendazole oxide has been shown to induce apoptosis in human cancer cell line HT-29, possibly by arresting the cell cycle at the G2/M phase.

Molecular weight: 281.33
Formula: C12H15N3O3S
CLOGP: 1.70
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 84.08
ALOGS: -2.50
ROTB: 5

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI

Approvals:

Date	Agency	Company	Orphan
Feb. 1, 1999	EMA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D000871	Anthelmintics
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000923	Anticestodal Agents
MeSH PA	D000977	Antiparasitic Agents
MeSH PA	D000980	Antiplatyhelmintic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.01	acidic
pKa2	3.44	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Tubulin alpha chain	Structural		TBA_HAECO					WOMBAT-PK

External reference:

ID	Source
D07106	KEGG_DRUG
C0051091	UMLSCUI
CHEBI:16959	CHEBI
CHEMBL1665	ChEMBL_ID
DB13871	DRUGBANK_ID
C027186	MESH_SUPPLEMENTAL_RECORD_UI
83969	PUBCHEM_CID
ALW	PDB_CHEM_ID
5979	INN_ID
J39B52TV34	UNII

Pharmaceutical products:

None